Abstract:<b><i>Introduction:</i></b> Due to variety of treatment alternatives for testicular tumours, parameters other than existing staging criteria are also needed. Most studies have revealed the correlation between cancer and inflammation. In this study, we aimed to investigate the value of preoperative inflammatory markers between early-stage testicular tumours and patients with advanced-stage, their relationship with tumour pathology and their importance in predicting stage. To calculate th… Show more
“…Statistically significant differences were shown between the median neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and systemic immuneinflammation index (SII) in early vs. advanced stages of seminomatous tumors, while within the nonseminomas, only a difference between the median platelet-to-lymphocyte ratio (PLR) was described. These data are in concordance with findings describing more intense immune cell infiltration in seminomatous than in nonseminomatous testicular tumors (25).…”
Section: Rationale For Immunotherapy In Testicular Cancersupporting
Testicular germ cell tumors (TGCTs) are malignancies with very high curative potential even in metastatic settings, mainly due to the introduction of cisplatin in the treatment of this disease. However, in a group of patients with cisplatin-refractory disease or with progressive disease despite high-dose salvage chemotherapy treatment, the prognosis is typically dismal. The triple combination of gemcitabine, oxaliplatin, and paclitaxel (GOP) has reasonable efficacy and is considered to be standard care for this group of patients. It remains to be seen, however, whether refractory TGCTs may represent a potential target for immune checkpoint inhibition. This review will focus on the rationale of the use of immunotherapy for platinum-refractory TGCTs and summarize data reporting experiences with immune checkpoint inhibitor treatment for this malignancy.
“…Statistically significant differences were shown between the median neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and systemic immuneinflammation index (SII) in early vs. advanced stages of seminomatous tumors, while within the nonseminomas, only a difference between the median platelet-to-lymphocyte ratio (PLR) was described. These data are in concordance with findings describing more intense immune cell infiltration in seminomatous than in nonseminomatous testicular tumors (25).…”
Section: Rationale For Immunotherapy In Testicular Cancersupporting
Testicular germ cell tumors (TGCTs) are malignancies with very high curative potential even in metastatic settings, mainly due to the introduction of cisplatin in the treatment of this disease. However, in a group of patients with cisplatin-refractory disease or with progressive disease despite high-dose salvage chemotherapy treatment, the prognosis is typically dismal. The triple combination of gemcitabine, oxaliplatin, and paclitaxel (GOP) has reasonable efficacy and is considered to be standard care for this group of patients. It remains to be seen, however, whether refractory TGCTs may represent a potential target for immune checkpoint inhibition. This review will focus on the rationale of the use of immunotherapy for platinum-refractory TGCTs and summarize data reporting experiences with immune checkpoint inhibitor treatment for this malignancy.
“…Although significant progresses have been made in terms of developing non-invasive prognostic biomarkers for CRC, the clinical appliance of the systematic inflammatory indices were regularly used, with its advantage of inexpensive, reliable, reproducible, robust and convenience 17 - 19 . Among all the systematic inflammatory indices, NLR and PLR were the most commonly used as prognostic biomarkers in CRC, which even had a discriminatory ability superior to other inflammatory biomarkers in resectable CRC 20 .…”
Objective: Synchronic colorectal peritoneal carcinomatosis (SCRPC) was recognized as a predictor of poor prognosis. The aim of this study was to investigate the role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) on the survival outcome, which might help determine the treatment management of SCRPC patients. Methods: A total of 103 SCRPC patients following cytoreduction surgery (CRS) and systematic chemotherapy (CT) between 1997 and 2013 in the First Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. The comparison of the clinicopathological variables and systematic inflammatory biomarkers, including NLR, PLR and SII, was performed by Chi-test and Cox regression analysis. According to the results of multivariate analysis, a prognostic nomogram was generated, and its prediction ability was measured by the concordance index (C-index). The survival curves were generated using the Kaplan-Meier method and survival comparison between groups was conducted via the log-rank test. Results: Univariate analysis revealed that elevated NLR, PLR and SII were significantly correlate with worse survival outcome. Only low SII value was recognized as an independent favorable prognostic factor for overall survival (HR=1.772, 95% CI=1.015-3.095, P=0.044), except for NLR and PLR. The nomogram could perform well in the prediction of overall survival in SCRPC patients (c-index 0.782). Moreover, SII had strong prognostic discriminatory ability to predict survival outcome for the patients receiving completeness of cytoreduction score (CCR) 0/1 or CCR2/3, rather than NLR and PLR. Conclusions: SII was a better inflammation factor to predict the outcomes of SCRPC patients receiving CRS and systematic CT. Low SII value was the most favorable factor benefiting from different level of CRS and it was useful for determining the appropriate treatment strategy for SCRPC patients.
“…SII, a novel inflammation-based biomarker combining platelet, neutrophil and lymphocyte counts, has been reported to be associated with clinical outcomes in several malignancies in many studies [9][10][11][12]. This is the first study to report a lower SII is associated with response to CRT in patients with HF.…”
Section: Resultsmentioning
confidence: 80%
“…It is calculated by the formula platelet count x neutrophil count /lymphocyte count and may be considered a combination NLR and PLR [9]. Many recent studies have demonstrated that SII is a strong independent predictor of major adverse events and prognosis in patients with several malignancies [9][10][11][12]. Patients with higher SII have increased recurrence rates, reduced survival and worse treatment response than patients with lower SII [9][10][11][12].…”
Section: Discussionmentioning
confidence: 99%
“…On the other hand, a novel parameter, combining neutrophil, lymphocyte and platelet counts, systemic immune-inflammation index (SII), as a promising inflammatory biomarker, has been described in recent years [9]. It has been reported that SII is associated with worse clinical outcomes in several malignancies [9][10][11][12]. However, the relationship between SII and response to CRT has not yet been investigated.…”
Aim: The systemic immune-inflammation index (SII), a novel inflammation-based biomarker combining platelet, neutrophil and lymphocyte counts, has been shown to be associated with worse clinical outcomes in several malignancies. However, the relationship between SII and response to cardiac resynchronization theraphy (CRT) has not been evaluated yet. The aim of this study was to investigate the association between SII and response to CRT in patients with heart failure (HF). Material and Methods: A total of 88 patients (54.5% male; mean age 58.9±12.9 years) who underwent CRT device implantation were included in the study. Baseline clinical, demographic, laboratory and echocardiographic data of patients' were recorded. An echocardiographic CRT response was defined as a decrease in left ventricular end-systolic volume of ≥15% and/or absolute increase of 5% in left ventricular ejection fraction (LVEF) at 6-month follow-up after CRT implantation. Results: Among included patients, a total of 51 (57.9%) patients were defined as ''responders'' after 6 months of CRT implantation. Lymphocyte count, LVEF and QRS width were significantly higher in responders compared to those responders. In addition, baseline creatinine and SII levels were significantly lower in responders than nonresponders. Multivariate logistic regression analysis showed that a SII of ≤973.3, LVEF and QRS width were independent predictors for response to CRT in the study population. Conclusion: SII may be used as a novel, simple and reliable inflammatory biomarker in the prediction of response to CRT in patients with HF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.